Data Highlights the Quantitative Detection of Neutralizing Activity Against Multiple SARS-CoV-2 Variants in Less Than 20 Minute Q-NAb Test
SANTA ANA, Calif., Sept. 20, 2022 /PRNewswire/ -- Autonomous Medical Devices Incorporated (AMDI) announced today that it will be presenting data on its Q-NAb™ Test at the 28th AACC International CPOCT Symposium: Meeting Evolving Patient Needs Using Point-of-Care Testing in Montreal September 21-23, 2022. The poster presentation is titled "Ultra-fast Quantitative Detection of Neutralizing Activity Against Multiple SARS-CoV-2 Variants".
"Today, measurement of the neutralizing antibody response to COVID-19 vaccines requires live virus testing in a BSL-3 laboratory. We are excited to show data demonstrating that the new Autolab-20TM and Q-NAb Test can quantitate the levels of neutralizing antibodies against all known strains of SARS-CoV-2 and re highly correlated with neutralization as measured by a live virus assay," said Dr. Sasha Perebikovsky, VP of Immunochemistry Systems.
"AMDI is proud to present performance data on its first product, the Q-NAb test. The ability to routinely measure quantitative neutralization activity in a sample has important research utility and may be important in patient management. We are preparing to launch the Q-NAb Test as an RUO in 2023 as we gather additional information needed to seek authorization of the Q-NAb test as a diagnostic product," explained David Okrongly, CEO of AMDI.
Autonomous Medical Devices Incorporated (AMDI) is an early-stage, California company focused on developing and manufacturing Autolabs and their associated test discs for human clinical diagnostics. Each of AMDI's Autolabs are small, portable point-of-care diagnostics devices using breakthrough microfluidics, hardware, and data/cloud connectivity to deliver lab quality results in <15 minutes. AMDI has built a world class, multi-disciplinary team of engineers, scientists, clinicians, and database experts and will launch its first Research Use Only (RUO) products in 2023 from its 110,000 square foot facility in Santa Ana, CA.
View original content:https://www.prnewswire.com/news-releases/data-highlights-the-quantitative-detection-of-neutralizing-activity-against-multiple-sars-cov-2-variants-in-less-than-20-minute-q-nab-test-301628130.html
SOURCE Autonomous Medical Devices Incorporated